Physician profile
Jayant V Ginde
NPI 1760464390
$1,375.53
in general payments reported to CMS, 2019-2025
14 companies · $40.14 in 2025
The $40.14 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $283 · 2020: $45.56 · 2021: $104 · 2022: $481 · 2023: $365 · 2024: $57.11 · 2025: $40.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $462.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $617.94 | 2019-2024 | |
| Boston Scientific Corporation | $138.38 | 2021-2022 | |
| Progenics Pharmaceuticals, INC. | $112.84 | 2022-2023 | Pylarify |
| Myovant Sciences INC. | $102.70 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $90.70 | 2022 | |
| Blue Earth Diagnostics | $71.01 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $50.89 | 2023 | |
| Palette Life Sciences, INC. | $41.96 | 2022-2023 | |
| Janssen Biotech, INC. | $41.04 | 2023-2024 | Erleada |
| Olympus America INC. | $40.14 | 2025 | Itind System |
| Tolmar Pharmaceuticals, INC. | $17.29 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $17.06 | 2023 | Lynparza |
| Angiodynamics, INC. | $16.96 | 2020 | |
| Tolmar, INC. | $16.62 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayant Ginde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.